Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock

Histogenics (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares.
As quoted in the press release:

The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions payable by Histogenics. Canaccord Genuity acted as the sole book-running manager for the offering.

Click here to read the full press release.